Related Experiment Video

Updated: Jun 14, 2026

Reprogramming Pancreatic Ductal Adenocarcinoma to Pluripotency
07:08

Reprogramming Pancreatic Ductal Adenocarcinoma to Pluripotency

Published on: February 2, 2024

Reactivation of p53 by novel MDM2 inhibitors: implications for pancreatic cancer therapy

Asfar S Azmi1, Philip A Philip, A Aboukameel

  • 1Department of Pathology, Karmanos Cancer Institute, Wayne State University School of Medicine, Detroit, MI 48201, USA.

Current Cancer Drug Targets
|April 8, 2010
PubMed

Insights

Novel MDM2 inhibitors (MI-319 & 219) show promise in pancreatic cancer by reactivating the p53 pathway, inhibiting tumor growth, and enhancing gemcitabine efficacy. These inhibitors target SIRT1 and Ku70, leading to apoptosis.

Area of Science:

  • Oncology
  • Molecular Biology
  • Cancer Therapeutics

Background:

  • Pancreatic cancer (PC) remains a challenging malignancy with limited treatment options.
  • The p53 pathway is frequently inactivated in cancer, making its reactivation a therapeutic target.
  • MDM2 inhibitors offer a strategy to restore p53 function.

Purpose of the Study:

  • To investigate the efficacy of novel MDM2 inhibitors (MI-319 & 219) in pancreatic cancer.
  • To elucidate the molecular mechanisms underlying their anti-cancer effects, including identification of secondary targets.
  • To evaluate the synergistic potential of these inhibitors with gemcitabine.

Main Methods:

  • Cell-based assays for growth inhibition and apoptosis.
  • Western blot and siRNA to analyze protein expression and pathway activation.
  • Immunoprecipitation and co-immunoprecipitation to study protein interactions.
  • Surface plasmon resonance for binding affinity.
  • In vivo xenograft studies in mice.

Main Results:

  • MI-319 and MI-219 induced significant growth inhibition and apoptosis in PC cells by reactivating the p53 pathway.
  • The inhibitors increased p53, p21(WAF1), and Puma levels, with p21(WAF1) being crucial for growth inhibition.
  • Secondary targets SIRT1 and Ku70 were identified, and MI-319 disrupted their interaction with Bax.
  • Combination therapy with gemcitabine showed synergistic anti-tumor effects.
  • Oral administration of MI-319 demonstrated significant tumor growth inhibition in wt-p53 xenografts without toxicity.

Conclusions:

  • Novel MDM2 inhibitors MI-319 and MI-219 are effective against pancreatic cancer by restoring p53 function.
  • SIRT1 and Ku70 are identified as novel secondary targets involved in the apoptotic mechanism.
  • These inhibitors show potential as combination therapy with gemcitabine and warrant clinical investigation for pancreatic cancer treatment.

More Related Videos

Studying Pancreatic Cancer Stem Cell Characteristics for Developing New Treatment Strategies07:29

Studying Pancreatic Cancer Stem Cell Characteristics for Developing New Treatment Strategies

Published on: June 20, 2015

Ultrasound-Guided Orthotopic Implantation of Murine Pancreatic Ductal Adenocarcinoma06:21

Ultrasound-Guided Orthotopic Implantation of Murine Pancreatic Ductal Adenocarcinoma

Published on: November 19, 2019

Related Concept Videos

Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the daughter...
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
DNA Damage can Stall the Cell Cycle02:36

DNA Damage can Stall the Cell Cycle

In response to DNA damage, cells can pause the cell cycle to assess and repair the breaks. However, the cell must check the DNA at certain critical stages during the cell cycle. If the cell cycle pauses before DNA replication, the cells will contain twice the amount of DNA. On the other hand, if cells arrest after DNA replication but before mitosis, they will contain four times the normal amount of DNA. With a host of specialized proteins at their disposal,cells must use the right protein at...
DNA Damage Can Stall the Cell Cycle02:36

DNA Damage Can Stall the Cell Cycle

In response to DNA damage, cells can pause the cell cycle to assess and repair the breaks. However, the cell must check the DNA at certain critical stages during the cell cycle. If the cell cycle pauses before DNA replication, the cells will contain twice the amount of DNA. On the other hand, if cells arrest after DNA replication but before mitosis, they will contain four times the normal amount of DNA. With a host of specialized proteins at their disposal,cells must use the right protein at...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...